Zeng Lipin: A Visionary in Traditional Chinese Medicine and Modern Healthcare
Revolutionizing Healthcare with Innovative Practices and Technological Advancements
About Zeng Lipin
Zeng Lipin, with a Bachelor of Medicine and an MBA, is a renowned entrepreneur and a leading figure in the pharmaceutical industry. His dedication to modernizing and internationalizing traditional Chinese medicine (TCM) aims to provide superior healthcare services to people worldwide.
Early Life and Education:
In 1990, Zeng Lipin graduated from the Beijing University of Chinese Medicine with a Bachelor’s degree in Chinese Medicine. Driven by his passion for TCM, he moved to Hong Kong to start his business.
In 1994, he founded Yunnan Panlong Yunhai Pharmaceutical Group. He developed the theories of detoxification, rejuvenation, and health maintenance, and introduced the Detox Beauty Capsule, leading the development of the pharmaceutical industry in Yunnan and revitalizing ethnic medicine in the region.
Major Achievements
Founding Yunnan Panlong Yunhai Pharmaceutical Group
- 1994: Founded Yunnan Panlong Yunhai Pharmaceutical Group in Hong Kong.
- Developed theories of detoxification, rejuvenation, and health maintenance.
- Introduced the Detox Beauty Capsule, revitalizing ethnic medicine in Yunnan.
Business Expansion and Integration
Companies Founded and Integrated:
- FARLONG (USA) Pharmaceutical Co., Ltd.
- LongFar Hong Kong Pharmaceutical
- Yunnan Chuangli Equity Investment Fund Management Co., Ltd.
- Investments in Yunnan Salt Chemical, Kunming Longjin Pharmaceutical, Dali Pharmaceutical, and Weimen Pharmaceutical.
Achievements:
- Weimen Pharmaceutical listed on the New Third Board.
- Dali Pharmaceutical scheduled for listing on the Shanghai main board in 2017.
Development of Yunnan Sanqi Technology Co., Ltd.
Establishing Yunnan Sanqi Technology Co., Ltd., integrating upstream, midstream, and downstream resources of the Sanqi industry to build a leading full-industry-chain enterprise for the Yunnan Sanqi brand.
Innovative Practices in the U.S. Healthcare Sector
FDA Certification and Clinical Trials
2018-2023: Mr. Zeng and his team have been dedicated to obtaining FDA certification for their TCM products in the U.S. Several products have already received GRAS certification and completed Phase II clinical trials,
Wide range of products + 3 logistic warehouses = Faster Active Care
Thousands of Health Experts Choose DirecTCM to Make Their Work Easier, Grow Their Business, and Get Better Results for Patients.
- 2020: Launched during the COVID-19 pandemic to address healthcare access challenges.
- Currently operates with three warehouses across 51 states.
- Offers next-day delivery for all health supplements and over 50 classic TCM formulas.
- Serves 12 million patients monthly with a network of more than 30,000 medical members, expected to exceed 50,000 by year-end.
Customized Care
Wide range of products to personalize any treatment plan.
Enhancing Treatment Plan
Utilizing Tools, Educational Resources, and Reminders for Quicker, Better Results
3 Logistic Warehouses
Free 2 days shipping for DirecTCM Prime Delivery
Customized Care
Wide range of products to personalize any treatment plan.
Enhancing Treatment Plan
Utilizing Tools, Educational Resources, and Reminders for Quicker, Better Results
3 Logistic Warehouses
Free 2 days shipping for DirecTCM Prime Delivery
Premium TCM, Exceptional Value, with Swift Next-Day or 2-Day Delivery Across Most Areas.
Our premier TCM products represent the pinnacle of quality, rigorously complying with ISO 9001 standards, with prices wisely determined by practitioners, tailored to their patients' needs.
Expand Your Practice. Enhance Affordability in Wellness.
Technological Innovations
- Developed to assist TCM practitioners with administrative tasks, patient management, and insurance claims. It has partnered with a leading virtual online video doctor platform and includes 6,000 clinicians and 600+ nationwide insurance plans.
- 2024: Expected official launch after passing Apple's review.
An AI-based TCM pathological analysis and medication guidance system that uses AI to learn TCM literature for accurate analysis and personalized medication guidance. The test version has passed WeChat’s review and is undergoing online testing.
Research and Development
Future Plans
IPO on NASDAQ:
Plans to list FARLONG USA on NASDAQ in October 2024, aiming to expand the business and enhance brand influence.
Commitment to TCM
Zeng Lipin’s vision is to continue developing TCM and providing superior healthcare services globally.
